Abstract:Background Systemic sclerosis (SSc) is an autoimmune disease characterized with multiple organ fibrosis. Previous studies showed transcription factor early growth response 1 (Egr1) overexpressed in the lesional skin of SSc patients, as well as Egr1 inducible genes1. Egr1 forms a positive feedback loop with master pro-fibrotic cytokine TGF and thus promotes fibrosis. Objectives To investigate the anti-fibrotic effect of a novel DMARD iguratimod in scleroderma models and patient skin grafts. Methods We used iguratimod to treat TGF-stimulated human skin fibroblast, bleomycin induced mice, tight skin 1 (TSK-1) mice and SSc skin grafts. The bleomycin model contained pre-establish fibrosis and late onset treatment. The skin grafts came from three SSc patients and was planted into irradiated nude mice. Results Iguratimod down-regulated egr1 expression in human skin fibroblast, with decreased collagen production and a-SMA expression. Knocking down Egr1 in fibroblast could mimic these effects. Both oral and topical iguratimod could reduce dermal thickening and collagen deposition in bleomycin induced skin fibrosis. a-SMA (+) myofibroblast counts, as well as Egr1 (+) and/or TGF (+) fibroblast counts in iguratimod treated groups were significantly less than the controls. Similarly, topical iguratimod ameliorated fibrosis with deduced dermal thickening in TSK-1 mice. Of note, 5-week iguratimod local injection remarkably reduced collagen content in skin grafts from three SSc patients. Staining of Egr1 and TGF in skin tissue were inhibited after iguratimod treatment simultaneously. Conclusion We found the potential of iguratimod to treat SSc, which was characterized as an Egr1 inhibitor. Further clinical investigation is needed to establish its safety and efficacy. References [1] Bhattacharyya S, Sargent JL, Du P, et al. Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PloS one 2011;6(9):e23082 doi: 10.1371/journal.pone.0023082 [2] Chen SJ, Ning H, Ishida W, et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. The Journal of biological chemistry 2006;281(30):21183-97 doi: 10.1074/jbc.M603270200 [2] Wu M, Melichian DS, de la Garza M, et al. Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. The American journal of pathology 2009;175(3):1041-55 doi: 10.2353/ajpath.2009. Acknowledgement This work is supported by National Natural Science Foundation of China (81601401). Disclosure of Interests None declared

Early Growth Response 3 (Egr-3) is Induced by Transforming Growth Factor-Β and Regulates Fibrogenic Responses.

The Early Growth Response Gene Egr2 (alias Krox20) is a Novel Transcriptional Target of Transforming Growth Factor-Β That is Up-Regulated in Systemic Sclerosis and Mediates Profibrotic Responses.

Essential Roles for Early Growth Response Transcription Factor Egr-1 in Tissue Fibrosis and Wound Healing

Smad-Independent Transforming Growth Factor-β Regulation of Early Growth Response-1 and Sustained Expression in Fibrosis

Early Growth Response Transcription Factors: Key Mediators of Fibrosis and Novel Targets for Anti-Fibrotic Therapy

Egr-1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis)

THU0355 IGURATIMOD MIGHT TREAT SCLERODERMA WITH INTERRUPTED EGR1/TGF-? LOOP

The Early Growth Response Factor-1 Is Involved in Stem Cell Factor (SCF)-induced Interleukin 13 Production by Mast Cells, but Is Dispensable for SCF-dependent Mast Cell Growth

Early Growth Response-1 Suppresses Human Fibrosarcoma Cell Invasion and Angiogenesis.

The early growth response factor-1 contributes to interleukin-13 production by mast cells in response to stem cell factor stimulation.

Epiregulin is a dendritic cell-derived EGFR ligand that maintains skin and lung fibrosis.

A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling

Mice Lacking the Transcriptional Regulator Egr3 Have Nerve Growth Factor (ngf) Signaling Defects and Profound Sympathetic Dysautonomia

[Transforming Growth Factor-Beta and Its Receptors in Scleroderma].

Transforming Growth Factor-β Receptor Type I-dependent Fibrogenic Gene Program is Mediated Via Activation of Smad1 and ERK1/2 Pathways

Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation

Toll-like Receptor 3 Upregulation by Type I Interferon in Healthy and Scleroderma Dermal Fibroblasts

Early growth response 2 (Egr2) plays opposing roles in committing C3H10T1/2 stem cells to adipocytes and smooth muscle-like cells.

Iguratimod Attenuated Fibrosis in Systemic Sclerosis Via Targeting Early Growth Response 1 Expression.

Early growth response protein 2 promotes partial epithelial-mesenchymal transition by phosphorylating Smad3 during renal fibrosis

Expression of Egr-1 in Late Stage Emphysema